AMI
11
2
2
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
9.1%
1 terminated out of 11 trials
75.0%
-11.5% vs benchmark
27%
3 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (11)
Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
SuperSaturated Oxygen Comprehensive Observational Registry
DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
High-Frequency QRS for Predicting Microvascular Dysfunction and Adverse Events After PCI in Acute Myocardial Infarction
Effects of Edoxaban on Platelet Aggregation
Baduanjin Sequential Therapy and Cardiac Function of AMI With Reduced EF After PCI
Influence of Beta Blockers on Prognosis in Patients With Acute Myocardial Infarction Complicated With Normal Ejection Fraction
The Pilot Project Development Of MEdical Rehabilitation System in Russian Federation
Lifestyle Intervention in a General Population for Prevention of Ischaemic Heart Disease
Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction
Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent